Nepali Reaches Summit of Everest for Record 30th Time 

Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
TT

Nepali Reaches Summit of Everest for Record 30th Time 

Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)
Veteran Sherpa guide Kami Rita returning after scaling Mount Everest for the 28th time arrives at the airport in Kathmandu, Nepal, May 25, 2023. (AP)

Nepali climber Kami Rita Sherpa broke his own record Wednesday as the person to have scaled Mount Everest the most times, achieving the milestone 30th ascent of the world's highest peak.

The 54-year-old, known as "Everest Man", reached the summit for the 29th time earlier this month, before climbing to the top again.

"Kami Rita reached the summit this morning. Now he has made a new record with 30 summits of Everest," Mingma Sherpa of Seven Summit Treks, his expedition organizer, told AFP.

A guide for more than two decades, Sherpa first stood on the 8,849-meter (29,000-foot) peak in 1994 when working for a commercial expedition.

Since then he has climbed Everest almost every year, guiding clients.

"I am glad for the record, but records are eventually broken," he told AFP after his 29th climb on May 12.

"I am more happy that my climbs help Nepal be recognized in the world."

Last year, Sherpa climbed Everest twice to reclaim his record after another guide, Pasang Dawa Sherpa, equaled his number of ascents.

Kami Rita Sherpa previously said that he has been "just working" and did not plan on setting records.

He has also conquered other 8,000-meter peaks including the world's second-highest mountain, K2 in Pakistan.

- Romanian climber dies -

His success on reaching the top came as the season's death toll climbed to five.

A Romanian climber died during a bid to scale Lhotse, the fourth-highest mountain, his expedition organizer said.

"He was found dead in his tent on Camp Three on Monday morning by his guide," said Mohan Lamsal of Makalu Adventure, naming the climber as Gabriel Viorel Tabara.

Everest and Lhotse share the same route until diverting at 7,200 meters.

"We are making efforts to bring his body down," he said.

Earlier this week, two Mongolian climbers went missing and were later found dead after summiting Everest.

Two more climbers, one French and one Nepali, have died this season on Makalu, the world's fifth-highest peak.

Nepal has issued more than 900 permits for its mountains this year, including 419 for Everest, earning more than $5 million in royalties.

Around 500 climbers and their guides have already reached the summit of Everest after a rope-fixing team reached the peak last month.

This year, China also reopened the Tibetan route to foreigners for the first time since closing it in 2020 because of the pandemic.

Nepal is home to eight of the world's 10 highest peaks and welcomes hundreds of adventurers each spring, when temperatures are warm and winds typically calm.

Last year more than 600 climbers made it to the summit of Everest, but it was also the deadliest season on the mountain, with 18 fatalities.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”